Increasing the rosuvastatin dose from 10 mg to 20 mg in combination with fenofibric acid 135 mg for up to 52 weeks resulted in significant ( p 0.005 for all comparisons ) mean percentage changes from baseline in LDL-C ( -9.5 % ) , non-HDL-C ( -6.0 % ) , ApoB ( -8.5 % ) , and HDL-C ( 3.6 % ) , while median TG levels remained largely unchanged ( 0.8 % , p = 0.055 ) at the week 52 visit .
